Warther Private Wealth LLC Has $230,000 Stock Position in AstraZeneca PLC (NASDAQ:AZN)

Warther Private Wealth LLC cut its holdings in AstraZeneca PLC (NASDAQ:AZN) by 17.2% during the 1st quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 3,134 shares of the company’s stock after selling 652 shares during the quarter. Warther Private Wealth LLC’s holdings in AstraZeneca were worth $230,000 at the end of the most recent reporting period.

Other large investors have also bought and sold shares of the company. Fairvoy Private Wealth LLC grew its stake in shares of AstraZeneca by 6.9% during the first quarter. Fairvoy Private Wealth LLC now owns 4,923 shares of the company’s stock worth $362,000 after buying an additional 317 shares during the last quarter. Optas LLC boosted its holdings in shares of AstraZeneca by 1.5% during the 1st quarter. Optas LLC now owns 15,574 shares of the company’s stock valued at $1,145,000 after acquiring an additional 229 shares in the last quarter. Asio Capital LLC grew its position in AstraZeneca by 1.2% during the 1st quarter. Asio Capital LLC now owns 54,170 shares of the company’s stock worth $3,981,000 after acquiring an additional 629 shares during the last quarter. Foster Victor Wealth Advisors LLC increased its holdings in AstraZeneca by 14.0% in the 1st quarter. Foster Victor Wealth Advisors LLC now owns 3,911 shares of the company’s stock worth $287,000 after purchasing an additional 480 shares in the last quarter. Finally, Ritholtz Wealth Management raised its position in AstraZeneca by 10.4% in the first quarter. Ritholtz Wealth Management now owns 75,471 shares of the company’s stock valued at $5,547,000 after purchasing an additional 7,101 shares during the last quarter. 20.35% of the stock is owned by institutional investors and hedge funds.

AstraZeneca Stock Performance

NASDAQ AZN opened at $74.42 on Monday. The company has a market capitalization of $230.80 billion, a price-to-earnings ratio of 32.93, a PEG ratio of 1.42 and a beta of 0.38. The company has a quick ratio of 0.74, a current ratio of 0.93 and a debt-to-equity ratio of 0.65. AstraZeneca PLC has a twelve month low of $61.24 and a twelve month high of $87.68. The stock has a fifty day simple moving average of $69.81 and a 200 day simple moving average of $70.31.

AstraZeneca (NASDAQ:AZN) last posted its quarterly earnings data on Tuesday, April 29th. The company reported $1.24 EPS for the quarter, beating analysts’ consensus estimates of $1.10 by $0.14. AstraZeneca had a net margin of 13.01% and a return on equity of 32.23%. The company had revenue of $13.59 billion for the quarter, compared to analyst estimates of $13.71 billion. During the same period in the prior year, the firm posted $2.06 EPS. The company’s quarterly revenue was up 7.2% on a year-over-year basis. Sell-side analysts expect that AstraZeneca PLC will post 4.51 EPS for the current year.

Analysts Set New Price Targets

Separately, BNP Paribas started coverage on AstraZeneca in a report on Tuesday, April 15th. They set an “outperform” rating and a $75.00 price target on the stock. One equities research analyst has rated the stock with a hold rating, five have issued a buy rating and two have assigned a strong buy rating to the company. According to data from MarketBeat, AstraZeneca has a consensus rating of “Buy” and a consensus target price of $85.00.

About AstraZeneca

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.